Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:31:30.175Z.
Calculation as of: 2026-10-06T16:31:30.175Z.
Quote observation: 2026-10-06T16:30:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d42caa3e816b0495fa2340ecfe28e9cd39b3fd8bb52e96b9f838481ccca068c7
PEG RATIO
N/A
C4 Therapeutics, Inc.
Market Cap
$317.88M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $317.88M | N/A |
| Avita Medical Inc. (RCEL)vs › | $320.74M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.85M | N/A |
| CapsoVision, Inc. (CV)vs › | $324.01M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $324.71M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $307.39M | N/A |
| Agenus Inc. (AGEN)vs › | $333.02M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $299.52M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
